AZ's Farxiga plus Onglyza non-inferior to Lantus in Phase IIIb for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Farxiga (Forxiga) dapagliflozin plus Onglyza saxagliptin met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c from

Read the full 252 word article

User Sign In